Skip to main content

Toronto CBD Firm Taps Ex-Acting U.S. Attorney General Whitaker For New Legal Advisor Role

Toronto-based CBD company Alternate Health Corp has hired Matthew Whitaker, former acting U.S. Attorney General, and his law firm Graves Garrett to serve as outside counsel. Best known for his brief tenure as U.S. Acting Attorney General after President Trump’s firing of firebrand cannabis foe Jeff Sessions, Whitaker generated controversy for his alleged ties to Trump and his comments about the Robert Mueller probe of Russian interference into the 2016 U.S. presidential election. In February 2019, Whitaker left his position after serving for only three months.

His appointment comes at a critical moment for Alternate Health, which recently stated that it was pivoting away from marijuana to focus more on hemp-derived CBD. Commenting on the high-profile hire, Alternate Health President Dr. Robert Blaine noted in a public statement how Whitaker is coming on board during a key inflection point for his company, currently divesting its cannabis assets.

“The legal environment surrounding CBD is rapidly evolving and it is essential that Alternate Health stays at the forefront of new government and FDA regulations,” he said. “We believe his experience in government and the Department of Justice is a significant asset as we move forward.”

Whitaker, who also served as Chief of Staff to then Attorney General Sessions from September 2017 to November 2018, is looking forward to his new role as a key legal advisor to Alternate Health. “I think there is serious potential in the CBD industry,” he said in a statement, “and everyone at Alternate Health will work hard to be a leader in the industry.”

According to Alternate Health, Whitaker will “tackle key issues” for the company. Foremost among them is “an investigation into certain actions in Canada by a California-based competitor.” When not conducting portentous probes into the misdeeds of unnamed rival companies, Whitaker’s other duties will include coordinating legal matters and developing Alternate Health’s “legal strategy as the company expands into new markets.”

Whitaker bears the distinction of being the latest high-ranking Republican to take his knowledge and juridical prowess to the cannabis/CBD/hemp market. John Boehner, former Speaker of the House, has become a very vocal champion of the space, even sitting on the board of Acreage Holdings, a New York-based multistate cannabis operator.

Whitaker’s skills working (or haggling) with D.C. lawmakers may be put to good use in his new position. Said Howard Mann, Alternate Health CEO, in a statement: “His knowledge and experience open doors at many of the most important institutions concerning our industry. I am also impressed with his toughness and tenacity he developed as a prosecutor, enforcing state and federal laws, examining alleged legal violations and setting a standard of fairness and justice.”

In addition to his serving as Acting U.S. Attorney General, Whitaker has donned other hats in the legal realm. This includes working as the U.S. Attorney for the Southern District of Iowa. In addition to his affiliation with the Graves Garrett law firm, Whitaker is also the managing director for Axiom Strategies/Clout Public Affairs.

Original Article Source: https://www.forbes.com/sites/irisdorbian/2019/08/28/toronto-cbd-firm-taps-ex-acting-u-s-attorney-general-whitaker-for-new-legal-advisor-role/

Comments

Post a Comment

Popular posts from this blog

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...
Post a Comment
Read more

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...
Post a Comment
Read more

Can Medical Marijuana Help Aging Parents With Dementia?

For decades, marijuana, even for medical uses, was demonized or questioned.  When states like Colorado legalized it for recreational use, more studies began to determine provable efficacy for its use as a medicine. The Federal government still classifies marijuana the same way it classifies heroin: harmful and with no medical benefits. Now we can see that this is wrong. When states legalized marijuana, referred to as cannabis here, they had an interest in getting data to see what good it could do. Proving efficacy could increase medical marijuana sales, benefit people who might at least find some medical use, and overall would bring tax dollars into the state coffers. Without funding studies, the Federal government has done very little to demonstrate what good cannabis can do. After all, if the presumption is that it helps nothing, there would be no motivation to determine with scientific data that it does anyone any good. But we have convincing data now about its beneficial use ...
Post a Comment
Read more